BLOG

Differential susceptibility and role for senescence in CAR T-cells based on costimulatory domains

17 August 2025

For decades, cancer treatment meant relying mostly on surgery, chemotherapy, and radiation. While these approaches have saved millions of lives, they often come with harsh side effects and don’t always stop cancer from coming back. “Then came a breakthrough that flipped cancer therapy on its head — CAR T-cell therapy.”

In CAR T-cell therapy, T cells are modified with a custom-made chimeric antigen receptor (CAR), enabling them to more effectively target and destroy cancer cells. Over time, multiple generations of CAR T-cells have been developed, differing in their structure, which in turn affects their efficacy and outcomes. A typical CAR T-cells has four main parts:

The Sensor (Antigen Recognition Domain), spots a unique flag (antigen) on cancer cells, telling the T cell, “That’s the enemy”

The Neck (Hinge Region), lets the sensor bend and reach cancer cells even if they’re hiding behind other cells.

The Strap (Transmembrane Domain), holds the CAR firmly on the T cell’s surface, just like a strap holds a helmet in place.

The Engine and Boosters (Signaling Domains), Inside the T cell, this part tells the cell to attack once the sensor spots a cancer cell. It Includes:

Engine (CD3ζ) – starts the killing process.

Booster (CD28 or 4-1BB) – makes the attack stronger and helps the cell last longer in the body.

A recent study revealed how CAR T-cell design influences their function. The researchers found that CAR T-cells containing a 4-1BB-based domain are more prone to enter an irreversible resting phase, in which they permanently stop functioning, often accompanied by inflammatory side effects. On the other hand, the cells which has CD28 domain cells were correlated with better outcomes.

Collectively, the findings confirm that, while CAR T therapy is revolutionary, it is not without limitations. Scientists are still learning how to make these cells stronger, longer-lasting, and effective against more types of cancer, including solid tumours. A key part of this puzzle is understanding why some CAR T cells lose effectiveness over time and identifying the best strategies to overcome these limitations.

- Medically reviewed by Dr. Prerna Chaudhary (Lead Scientist) at SunAct - Advanced Cancer Therapies.

Facebook
Twitter
LinkedIn
Email

Have Questions?

Fill in the details below.

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male